TIDMGEN
Company Announcement
COPENHAGEN, Denmark; June 28, 2021 --
https://www.globenewswire.com/Tracker?data=XfneYZ8hQc-zt6HueS1aKXJXhZdEgTMPI2KQiYhHOxf8UtE6C9C3hp-jIMa-5QtyvtBK7JZdUHbwV-LFw_PQeQ==
Genmab A/S (Nasdaq: GMAB). On February 23, 2021 Genmab announced
the initiation of a share buy-back program to mitigate dilution
from warrant exercises and to honor our commitments under our
Restricted Stock Units program.
The share buy-back program is expected to be completed no later
than June 30, 2021 and comprises up to 200,000 shares.
The following transactions were executed under the program from
June 21, 2021, to June 25, 2021:
Average price
No. of shares (DKK) Total value (DKK)
------------------------- ------------- ----------------- -----------------
Accumulated through last
announcement 181,800 398,391,489
June 21, 2021 1,700 2,694.12 4,580,004
June 22, 2021 2,500 2,687.12 6,717,800
June 23, 2021 2,400 2,648.29 6,355,896
June 24, 2021 2,500 2,603.72 6,509,300
June 25, 2021 2,500 2,607.15 6,517,875
Total 11,600 30,680,875
------------------------- ------------- ----------------- -----------------
Accumulated under the
program 193,400 429,072,364
Details of each transaction are included as an appendix to this
announcement.
Following these transactions, Genmab holds 292,606 shares as
treasury shares, corresponding to 0.45% of the total share capital
and voting rights.
The share buy-back program is undertaken in accordance with
Regulation (EU) No. 596/2014 ('MAR') and the Commission Delegated
Regulation (EU) 2016/1052, also referred to as the "Safe Harbour
Regulation." Further details on the terms of the share buy-back
program can be found in our company announcement no. 11 dated
February 23, 2021.
About Genmab
Genmab is an international biotechnology company with a core
purpose to improve the lives of patients with cancer. Founded in
1999, Genmab is the creator of multiple approved antibody
therapeutics that are marketed by its partners. The company aims to
create, develop and commercialize differentiated therapies by
leveraging next-generation antibody technologies, expertise in
antibody biology, translational research and data sciences and
strategic partnerships. To create novel therapies, Genmab utilizes
its next-generation antibody technologies, which are the result of
its collaborative company culture and a deep passion for
innovation. Genmab's proprietary pipeline consists of modified
antibody candidates, including bispecific T-cell engagers and
next-generation immune checkpoint modulators, effector function
enhanced antibodies and antibody-drug conjugates. The company is
headquartered in Copenhagen, Denmark with locations in Utrecht, the
Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more
information, please visit Genmab.com
https://www.globenewswire.com/Tracker?data=XfneYZ8hQc-zt6HueS1aKWPZdc3X_mfVZ7SVELI55cJQVNgiApgXxBMwcDGBj88waTOdALCgjUYm7PnkMYBaZQ==
.
Contact:
Marisol Peron, Senior Vice President, Global Investor Relations
& Communications
T: +1 609 524 0065; E: mmp@genmab.com
https://www.globenewswire.com/Tracker?data=6JSvIshwhShVwfg-Y24yY7Sqp5qRKhPxRxtuypwXLL6q0ge4uJNoSTTDbyUQIsTr3Ra6wbHK5BDI3diLfKZspQ==
For Investor Relations:
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
https://www.globenewswire.com/Tracker?data=skk8LoaZUSoSk9QyVDKBWb9GUS82XzGRV7wSuzRGw62Dqpyqw-ukFFKcJHuvvyNgGBkdBiROPyTgTyAr6-nC1g==
This Company Announcement contains forward looking statements.
The words "believe", "expect", "anticipate", "intend" and "plan"
and similar expressions identify forward looking statements. Actual
results or performance may differ materially from any future
results or performance expressed or implied by such statements. The
important factors that could cause our actual results or
performance to differ materially include, among others, risks
associated with pre-clinical and clinical development of products,
uncertainties related to the outcome and conduct of clinical trials
including unforeseen safety issues, uncertainties related to
product manufacturing, the lack of market acceptance of our
products, our inability to manage growth, the competitive
environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and
proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our
products or technologies obsolete, and other factors. For a further
discussion of these risks, please refer to the risk management
sections in Genmab's most recent financial reports, which are
available on
https://www.globenewswire.com/Tracker?data=RVA03MXECD26ma5dZaJPlyHbs5Nt1oUe_ewoC2rGEphvyJitjZmFKpkksXUe0dKw3Uehm53q_BU-MQWPO11Tug==
www.genmab.com and the risk factors included in Genmab's most
recent Annual Report on Form 20-F and other filings with the U.S.
Securities and Exchange Commission (SEC), which are available at
https://www.globenewswire.com/Tracker?data=RVA03MXECD26ma5dZaJPl4FRfSeHGKZtmBdQix4kCrFF6YMpmi_Qn6N7pE-Y_LkKFDYj2NgwlZpvyG-569-bdziHVqmLg8XyMYzbMq_856g=
www.sec.gov. Genmab does not undertake any obligation to update or
revise forward looking statements in this Company Announcement nor
to confirm such statements to reflect subsequent events or
circumstances after the date made or in relation to actual results,
unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks:
Genmab(R) ; the Y-shaped Genmab logo(R) ; Genmab in combination
with the Y-shaped Genmab logo(R) ; HuMax(R) ; DuoBody(R) ; DuoBody
in combination with the DuoBody logo(R) ; HexaBody(R) ; HexaBody in
combination with the HexaBody logo(R) ; DuoHexaBody(R) and
HexElect(R) .
Company Announcement no. 55
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122
Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V
Denmark
Attachments
-- 210628_CA55_Transactions in connection with share buy-back program
https://ml-eu.globenewswire.com/Resource/Download/4a4f1cb3-43a0-4e7f-9233-46a4aca9f7eb
-- 210628_CA55_Appendix_Specification for June 21-25
https://ml-eu.globenewswire.com/Resource/Download/ee387055-08cc-47d6-8d9d-5873a2df0fdf
(END) Dow Jones Newswires
June 28, 2021 03:30 ET (07:30 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Genuit (LSE:GEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genuit (LSE:GEN)
Historical Stock Chart
From Apr 2023 to Apr 2024